Genovis AB

GENO

SE0002485979

Medical Equipment, Supplies & Distribution

Delayed Nasdaq Stockholm Other stock markets 04:24:35 2024-06-03 am EDT			5-day change	1st Jan Change
38.05 ^SEK	-0.52%		+8.56%	-26.83%

May. 15	Genovis AB (publ.) Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Mar. 14	Carthesian Therapeutics Terminates Genovis AB (Publ.) Licence Agreement	CI

Genovis AB (Publ.) Announces Executive Changes

May 20, 2021 at 05:09 am EDT

Genovis AB (publ.) at its AGM held on May 20, 2021, Steve Jordanwas elected new Board member and Torben Jørgensenwas elected Chairperson of the Board.

Latest news about Genovis AB

Genovis AB (publ.) Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 15	CI
Carthesian Therapeutics Terminates Genovis AB (Publ.) Licence Agreement	Mar. 14	CI
Genovis AB (publ.) Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 15	CI
Genovis AB (publ.) Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 15	CI
Genovis to Get $1 Million Milestone Payment for Xork Development	Feb. 13	MT
Genovis AB (publ.) Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 15	CI
Genovis AB (publ.) Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-24	CI
Genovis Launch Innovative Igm-Specific Protease with Wide-Ranging Applications in Life Science Markets	23-06-02	CI
Genovis AB (publ.) Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-16	CI
ArcticZymes Technologies ASA and Genovis AB Announce Collaboration to Speed Up Penetration and Growth in the Chinese Market	23-05-03	CI
Genovis AB (publ.) Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-02-15	CI
Genovis AB (publ.) Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-15	CI
Genovis AB (publ.) Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-15	CI
Genovis AB (publ.) Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-12	CI
Genovis Signs Supply Agreement With US Biotech Company; Shares Rise 7%	22-08-10	MT
Genovis AB Enters Licensing and Supply Agreement with New Bioprocess Customer	22-08-10	CI
Genovis Starts Service Agreement with Swiss Biotech Company evitria	22-08-04	MT
Genovis AB Enters Service Agreement with Evitria Ag for Fast LC_MSlysis of Recombinant Antibodies	22-08-04	CI
Genovis AB (Publ.) Announces Board Changes	22-05-12	CI
Genovis AB (publ.) Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-27	CI
Genovis AB (publ.) Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2021	22-02-08	CI
Genovis AB (publ.) Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-12	CI
Genovis AB Announces Exclusive License Agreement with Selecta Bioscience to Develop and Promote A Novel Igg Protease in Gene Therapy and Autoimmune Disease	21-10-21	CI
Genovis' : New CFO To Assume Role January 2022	21-10-06	MT
Genovis AB (Publ.) Hires Magnus Långberg as the New CFO	21-10-06	CI

Genovis AB is a Sweden-based company engaged in the research and development, production and marketing of technologies and products for cellular research. The Company offers products within two product portfolios, namely protein portfolio and nano portfolio. The protein portfolio develops products within the areas of cancer, inflammatory and autoimmune diseases. The portfolio comprises FabRICATOR, a genetically modified enzyme the cleaves antibodies in two parts, and IgGZERO, a protein that specifically cleaves the sugar molecules that occur naturally on antibodies. The products within the nano portfolio are primarily directed at the preclinical market. The Company markets and sells its products through dealers and distributors in the European, North American and Asian continents. As of December 31, 2011, it operated a wholly owned subsidiary, Eijdo Research AB.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-08-20 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Genovis AB

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

38.25 SEK

Average target price

51.5 SEK

Spread / Average Target

+34.64%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Diagnostic & Testing Substances

	1st Jan change	Capi.
GENOVIS AB	-26.83%	238M
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-3.17%	8.22B
DIASORIN S.P.A.	+6.91%	5.72B
LANTHEUS HOLDINGS, INC.	+31.98%	5.67B
AUTOBIO DIAGNOSTICS CO., LTD.	-10.03%	4.11B
10X GENOMICS, INC.	-59.94%	2.68B
ANDON HEALTH CO., LTD.	+11.23%	2.68B
VITROLIFE AB	-5.14%	2.37B
MYRIAD GENETICS, INC.	+18.91%	2.06B
GUANGZHOU WONDFO BIOTECH CO.,LTD	-7.56%	1.8B

Diagnostic & Testing Substances

Genovis AB

Equities

GENO

SE0002485979

Medical Equipment, Supplies & Distribution

Genovis AB (Publ.) Announces Executive Changes

Latest news about Genovis AB

Chart Genovis AB

Company Profile

Income Statement Evolution

Ratings for Genovis AB

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Diagnostic & Testing Substances